Black Diamond Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $103.83M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | – | $-0.17 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-0.16 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | During market hours | – | $-0.27 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.19 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | Before market open | – | – | – |
Press releases
Announcements Black Diamond Therapeutics filed with the SEC
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Servier and Black Diamond Therapeutics
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Thank You Partnership: [email protected] Investors: [email protected] Media: [email protected]
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Announces Restructuring
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Black Diamond Therapeutics Announces Initial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Announces Corporate
Regulation FD disclosure · EX-99.1 to Form 8-K
BDTX - 4933: Potential Best - in - Class Brain - Penetrant RAF MasterKey Inhibitor
Regulation FD disclosure · EX-99.2 to Form 8-K
Black Diamond Therapeutics Announces Topline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Announces CEO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Announces Initial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Black Diamond Therapeutics Announces Pipeline
Regulation FD disclosure · EX-99.1 to Form 8-K
BDTX - 1535 Brain - Penetrant Inhibitor of GBM and NSCLC MasterKey EGFR Mutations
Regulation FD disclosure · EX-99.2 to Form 8-K
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Strategic Priorities and Expected Milestones for 2022
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pioneering the Development of MasterKey Therapies
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K